Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-11
2008-03-11
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S121000
Reexamination Certificate
active
11100535
ABSTRACT:
Substituted C-imidazo [1,2-a]pyridine-3-yl methylamines and physiologically acceptable salts thereof, a method for the production thereof, pharmaceutical compositions containing these compounds, and pharmaceutical uses thereof, e.g., as NO synthase inhibitors.
REFERENCES:
patent: 2002/0042420 (2002-04-01), Briem et al.
patent: 2005/0239823 (2005-10-01), Oberboersch et al.
patent: 197 34 184 (1999-02-01), None
patent: 1 536 351 (1968-07-01), None
patent: WO 96/34866 (1996-11-01), None
patent: WO 01/27109 (2001-04-01), None
patent: WO 02/14313 (2002-02-01), None
patent: WO 02/066477 (2002-08-01), None
patent: WO 02/066478 (2002-08-01), None
CASREACT 65:3958, abstract only of Almirante et al,. bollettino Chimico Farmaceutico, 1966, vol. 105, pp. 32-44.
Freshney, Culture of animal cells, a manual of basic technique, 1983, pp. 1-6.□□.
Dermer et al, Bio/Technology, vol. 12, pp. 320, 1994.
International Search Report dated Feb. 10, 2004 (Two (2) pages).
German Search Report dated Jun. 3, 2003 with English translation of relevant portion (Eight (8) pages).
Kamisnki, et al., “Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective, and Metabolic Properties of Substituted Imidazo[1,2-a]pyridines and Analogues”,J. Med. Chem, vol. 30, 1987, pp. 2031-2046.
Almirante, et al., “Syntheses and Reactions of Imidazoles”,Bollettino Chimico Farmaceutico, vol. 105, No. 1, 1966.
L. H. Lassen, et al., “Nitric oxide synthase inhibition in migraine” The Lancet, vol. 349, Feb. 8, 1997, pp. 401-402.
Lars Lykke Thomsen, et al., “Nitric Oxide Theory of Migraine” Clinical Neuroscience, vol. 5, 1998, pp. 28-33.
P. E. Chabrier, et al., “Nitric oxide synthases: targets for therapeutic strategies in neurological diseases” CMLS, Cell. Mol. Life Science, vol. 55, 1999, pp. 1029-1035.
I. C. Green, et al., “Nitric oxide: from basic research to clinical applications” DDT, vol. 4, No. 2, Feb. 1999, pp. 47-49.
Adrian J. Hobbs, et al., “Inhibition of Nitric Oxide Synthase as a Potential Therapeutic Target” Annu. Rev. Pharmacol. Toxicol, vol. 39, 1999, pp. 191-220.
Houben-Weyl, “1.4.3.5 Addition of Enamines to Iminium Ions”, vol. E 21, pp. 1925-1929.
Merla et al., “Efficient Synthesis of γ-Oxo- and γ -Hydroxy-α-amino Acids”,Synthesis, Nov. 1998, pp. 1609-1614.
Ferid Murad, “Discovery of Some of the Biological Effects of Nitric Oxide and Its Role in Cell Signaling (Nobel Lecture)” Angew. Chem. Int. Ed., vol. 38, 1999, pp. 1857-1868.
Louis J. Ignarro, “Stickstoffmonoxid: ein einzigartiges endogenes Signalmolekuel in der Gefaessbiologie (Nobel-Vortrag)” Angew. Chem. vol. 111, 1999, pp. 2002-2013.
Hennies Hagen-Heinrich
Oberboersch Stefan
Sundermann Bernd
Sundermann Corinna
Crowell & Moring LLP
Gruenenthal GmbH
Rahmani Niloofar
Seaman Margaret D.
LandOfFree
Substituted C -imidazo[1,2-a]pyridin-3-yl-methylamines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted C -imidazo[1,2-a]pyridin-3-yl-methylamines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted C -imidazo[1,2-a]pyridin-3-yl-methylamines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3910188